Phase II Study of bi-weekly SOX+Cetuximab for EGFR positive and K-ras wild type dvanced and recurrent Colorectal Cancer
Phase 2
- Conditions
- Colorectal Cancer
- Registration Number
- JPRN-UMIN000005884
- Lead Sponsor
- Jikei Medical University School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Not provided
Exclusion Criteria
1)Serious complications(intestinal paralysis and intestinal obstruction, interstitial pneumonia, pulmonary fibrosis, renal failure, cardiac failure , liver failure) 2)History of serious drug hypersensitivity 3)Peripheral neuropathy 4)without helpes simplex 5)Requiring flucytosine. 6)History of serious Infusional reaction. 7)Active infection. 8)renal dysfuncsion serum creatinine <= 1.2 mg/dL (CCr) 60mL/min <= 9)Pregnant or lactating woman 10)Active other malignancies. 11)Symptomatic brain metastasis 12)Atopic delmatitis 13)Not appropriate for the study at the physician's assessment
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method